Want to see JP:4582 full AI Analyst Report?
4582 Stock Chart & Stats
¥90.00
¥6.00(2.96%)
At close: 4:00 PM EST
¥90.00
¥6.00(2.96%)
Day’s Range― - ―
52-Week Range¥66.00 - ¥229.00
Previous CloseN/A
Volume447.50K
Average Volume (3M)577.10K
Market Cap
¥5.34B
Enterprise Value¥6.62K
Total Cash (Recent Filing)¥1.90B
Total Debt (Recent Filing)¥1.03B
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-106.26
Shares Outstanding76,434,210
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA still-healthy gross margin indicates strong unit economics and pricing power in manufacturing or core products. Over 2–6 months this supports margin recovery if operating costs are controlled, affords buffer against pricing pressure, and increases upside from any revenue stabilization.
Diversified Revenue ModelMultiple revenue streams—direct sales, collaboration payments, milestones and licensing—provide structural diversification. This reduces dependence on a single product, enables milestone-driven cash inflections, and allows partnerships to de‑risk R&D and accelerate commercialization over the medium term.
Specialty/oncology Focus In JapanConcentrating on specialty and oncology in Japan targets areas with higher pricing, entrenched clinical demand, and regulatory barriers to entry. Lifecycle management expertise and local commercialization strength create sustainable competitive advantages and recurring revenue potential over multiple quarters.
Bears Say
Sharp Revenue DeclineA multiyear, steep revenue drop erodes scale and operating leverage, limiting funds for R&D and commercialization. Persistent top-line decline often signals lost market share or product transitions and makes sustainable recovery dependent on successful new product launches or partner deals.
Negative Operating And Free Cash FlowSustained negative OCF and FCF increase reliance on external financing and heighten liquidity risk. For a pharma firm with long development cycles, weak cash generation constrains trial funding and commercialization, raising the probability of dilutive or costly financing if losses persist.
Rising Leverage And Compressed EquityNew debt elevates fixed obligations and interest burden while equity erosion reduces balance-sheet flexibility. Higher leverage limits strategic optionality—slowing M&A, partnerships or investment—and increases refinancing and solvency risks if operating performance does not improve.
Symbio Pharmaceuticals Limited News
4582 FAQ
What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?
Symbio Pharmaceuticals Limited lowest stock price was ¥66.00 and its highest was ¥229.00 in the past 12 months.
What is Symbio Pharmaceuticals Limited’s market cap?
Symbio Pharmaceuticals Limited’s market cap is ¥5.34B.
When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?
Symbio Pharmaceuticals Limited’s upcoming earnings report date is Jul 30, 2026 which is in 3 days.
How were Symbio Pharmaceuticals Limited’s earnings last quarter?
Symbio Pharmaceuticals Limited released its earnings results on May 07, 2026. The company reported -¥35.89 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Symbio Pharmaceuticals Limited overvalued?
According to Wall Street analysts Symbio Pharmaceuticals Limited’s price is currently Overvalued.
Does Symbio Pharmaceuticals Limited pay dividends?
Symbio Pharmaceuticals Limited does not currently pay dividends.
What is Symbio Pharmaceuticals Limited’s EPS estimate?
Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Symbio Pharmaceuticals Limited have?
Symbio Pharmaceuticals Limited has 76,434,210 shares outstanding.
What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?
Symbio Pharmaceuticals Limited reported an EPS of -¥35.89 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in JP:4582
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Symbio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
Technical Analysis
Solasia Pharma KK
―
Wakamoto Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Medrx Co., Ltd.
―